GI Dynamics announces data demonstrating immediate and sustained reduction in HbA1c in patients with type 2 diabetes using EndoBarrier™ Gastrointestinal Liner. Compelling clinical data highlighted at first World Congress on Interventional Therapies for Type 2 Diabetes show improved glycemic control and weight reduction in uncontrolled diabetics.

For the first time, researchers have identified variations in a single gene that are strongly associated with kidney diseases disproportionately affecting African-Americans. This work was conducted by researchers at the National Institutes of Health (NIH) and by NIH-funded investigators at the Johns Hopkins University.

Many times you click on a publication about diabetes and you find out that most of the people involved have no real relation to diabetes. Everyone knows that Steve and I have been involved in patient care for years. We have taken it one step further with Andrew Young, coming …

Obese people with diabetes are just as likely to go undiagnosed as their slimmer peers with the disease, Harvard Medical School researchers report.

A study by researchers from the Joslin Diabetes Center has shown for the first time that more than half of patients with type 2 diabetes who enrolled in a novel short-term weight management program were able to maintain the weight loss they achieved during the program on their own long-term. …

New research reports that Januvia is currently prescribed most often as a third- or later-line of therapy for the treatment of type 2 diabetes.

A large study of Swedish twins indicates that a common genetic cause underlies both low birth weight and the propensity to develop type 2 diabetes.

New research shows that low vitamin D levels can increase the risk for developing diabetes.

We continue to see healthcare costs rising and those with diabetes will certainly feel it the most. Let’s hope that the new president will do something to help. Consider getting involved with one of the presidential candidates after viewing their ideas on improving healthcare in this country.

The use of 80mg of atorvastatin reduced the relative risk of major cardiovascular events by 35% in patients with diabetes and CKD (20.9% vs 13.9%) and by 10% in patients with diabetes and normal eGFR (14.1% vs 12.8%).